RxDoctor Payments Data

Timothy Daugherty, MD

Internal Medicine · Savannah, GANPI 1821031840

Payments from drug & device makers

$7,953in general payments, 2019–2025

Across 498 payments — averaging $15.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$982
  • Amgen$758
  • Novartis$720
  • Astellas Pharma US Inc$424
  • Johnson & Johnson$340
  • plus $3K from 38 others

What the payments were for

  • Food & beverage$7,87199%
  • Education$821%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,953 in reported general payments places this provider in the 90th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$388,681
Medicare patients
598
Services billed
4,565

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide240$397,865
EliquisApixaban155$160,347
FarxigaDapagliflozin Propanediol116$127,556
JardianceEmpagliflozin63$77,449
MounjaroTirzepatide43$76,989
Trelegy ElliptaFluticasone/Umeclidin/Vilanter65$72,504
GemtesaVibegron71$58,125
Diclofenac Sodium27$42,749
LinzessLinaclotide30$36,246
TrulicityDulaglutide21$32,542
Repatha SureclickEvolocumab23$31,605
VascepaIcosapent Ethyl54$30,770
XareltoRivaroxaban24$29,391
VraylarCariprazine Hcl14$24,980
MyrbetriqMirabegron15$15,214

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$982$397,865240 claims
PfizerEliquis, Premarin, Abrysvo$317$172,191186 claims
AstraZenecaFarxiga$276$127,556116 claims
Lilly USA, LLCMounjaro, Trulicity$144$109,53164 claims
GSKTrelegy Ellipta, Arexvy$192$78,62487 claims
Boehringer IngelheimJardiance$134$77,44963 claims
AbbVieLinzess, Vraylar$1,525$61,22744 claims
Sumitomo Pharma America, Inc.Gemtesa$85$58,12571 claims
Johnson & JohnsonXarelto$340$29,39124 claims
Astellas Pharma US IncMyrbetriq$424$15,21415 claims
Esperion Therapeutics, Inc.Nexlizet$247$10,03915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Savannah

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →